MedTrace Logo

Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation

NCT00130910 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2007-11-15

No results posted yet for this study

Summary

Identifying methods to slow disease progression in patients with HIV-1 infection remains a top priority in many regions of the world. In many countries, medications known to slow progression are not readily affordable or available. Many of the individuals living in these countries are also co-infected with a variety of other diseases such as tuberculosis, malaria and soil-transmitted helminths. There are data to suggest that infection with these agents may activate the immune system in HIV-1 co-infected individuals and may lead to more rapid HIV disease progression. This study will evaluate the potential impact of treating helminths in HIV-1 seropositive individuals. Markers of disease progression and immune activation will be assessed. We will also measure the amount of virus in genital secretions to determine if treatment of co-infection can reduce the infectiousness of HIV in these individuals.

Conditions

  • HIV Infections
  • Helminthiasis

Interventions

DRUG

Albendazole

Albendazole 400mg x 3 first dose observed

DRUG

Placebo

Albendazole Placebo 400mg x 3 first dose observed

Sponsors & Collaborators

  • Kenya Medical Research Institute

    collaborator OTHER

  • University of Nairobi

    collaborator OTHER

  • Kenyatta National Hospital

    collaborator OTHER_GOV

  • University of Washington

    lead OTHER

Principal Investigators

  • Judd L Walson, MD, MPH · University of Washington

  • Grace C. John-Stewart, MD, PhD, MPH · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Completion
2007-06-30

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130910 on ClinicalTrials.gov